1. ¹Division of Hematology and Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA
2. ²Department of Pathology, Oregon Health & Science University, Portland, OR, USA
3. ³Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA

Correspondence: RM Braziel, Department of Pathology, L471, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. Fax: 1-503-494-6787

Received 4 July 2002; Accepted 7 November 2002.

Abstract

Imatinib mesylate, an Abl-specific kinase inhibitor, produces sustained complete hematologic responses (CHR) and major cytogenetic responses (MCR) in chronic myeloid leukemia (CML) patients, but long-term outcomes in these patients are not yet known. This article reports the identification of clonal abnormalities in cells lacking detectable Philadelphia (Ph) chromosome/BCR–ABL rearrangements from seven patients with chronic- or accelerated-phase CML, who were treated with imatinib. All seven patients were refractory or intolerant to interferon therapy. Six of seven patients demonstrated MCR and one patient, who had a cryptic translocation, achieved low-level positivity (2.5%) for BCR–ABL by fluorescence in situ hybridization. The median duration of imatinib treatment before the identification of cytogenetic abnormalities in BCR–ABL-negative cells was 13 months. The most common cytogenetic abnormality was trisomy 8, documented in three patients. All patients had varying degrees of dysplastic morphologic abnormalities. One patient exhibited increased numbers of marrow blasts, yet consistently demonstrated no Ph-positive metaphases and the absence of morphologic features of CML. The presence of clonal abnormalities in Ph-negative cells of imatinib-treated CML patients with MCR and CHR highlights the importance of routine metaphase cytogenetic testing and long-term follow-up of all imatinib-treated patients.